CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED
CA209-1533
Phase 2 small_molecule active
Quick answer
CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED for Non-small cell lung cancer (NSCLC) is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Non-small cell lung cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active